Loading
A phase 2 trial of onvansertib in lung cancer, run by University of Maryland, Baltimore, now recruiting.
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer is a phase 2, interventional study registered as NCT05450965 by University of Maryland, Baltimore, with a registry enrolment figure of 37 participants, started 2022-07-19 and due to reach its primary completion in 2027-08-31. Interventions recorded: Onvansertib. Conditions listed: Small-cell Lung Cancer; Small Cell Lung Carcinoma. Primary outcome: Objective Response Rate (ORR). Lung eligibility wording from the registry: "Patients must have histologically or cytologically confirmed small cell lung cancer". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.